A4S: A user-friendly graphical tool for pharmacokinetic and pharmacodynamic (PK/PD) simulation
暂无分享,去创建一个
[1] Lawrence F. Shampine,et al. Solving Index-1 DAEs in MATLAB and Simulink , 1999, SIAM Rev..
[2] B. Corrigan,et al. How Modeling and Simulation Have Enhanced Decision Making in New Drug Development , 2005, Journal of Pharmacokinetics and Pharmacodynamics.
[3] Mats O Karlsson,et al. Pharmacokinetic/pharmacodynamic modelling in oncological drug development. , 2005, Basic & clinical pharmacology & toxicology.
[4] J. Black,et al. Operational models of pharmacological agonism , 1983, Proceedings of the Royal Society of London. Series B. Biological Sciences.
[5] Paolo Magni,et al. TGI-Simulator: A visual tool to support the preclinical phase of the drug discovery process by assessing in silico the effect of an anticancer drug , 2012, Comput. Methods Programs Biomed..
[6] Michael Rowley,et al. Pharmacodynamic-pharmacokinetic integration as a guide to medicinal chemistry. , 2011, Current topics in medicinal chemistry.
[7] Johan Gabrielsson,et al. Pharmacokinetic-pharmacodynamic reasoning in drug discovery and early development. , 2009, Future medicinal chemistry.
[8] Paolo Magni,et al. Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents , 2004, Cancer Research.
[9] Neil J Attkins,et al. Quantitative pharmacological analysis of antagonist binding kinetics at CRF1 receptors in vitro and in vivo , 2011, British journal of pharmacology.
[10] C. Mehta,et al. The future of drug development: advancing clinical trial design , 2009, Nature Reviews Drug Discovery.
[11] D R Mould,et al. Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development , 2012, CPT: pharmacometrics & systems pharmacology.
[12] C Garnett,et al. Impact of Pharmacometric Reviews on New Drug Approval and Labeling Decisions—a Survey of 31 New Drug Applications Submitted Between 2005 and 2006 , 2007, Clinical pharmacology and therapeutics.
[13] L Aarons,et al. Role of modelling and simulation in Phase I drug development. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[14] Per Olsson,et al. Modelling and simulation to improve decision-making in clinical development , 2005 .
[15] L P Balant,et al. Modelling during drug development. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[16] Lawrence F. Shampine,et al. The MATLAB ODE Suite , 1997, SIAM J. Sci. Comput..
[17] L. Goodman,et al. The Pharmacological Basis of Therapeutics , 1941 .
[18] Jürgen Brockmöller,et al. Simulation of complex pharmacokinetic models in Microsoft EXCEL , 2007, Comput. Methods Programs Biomed..
[19] W Ewy,et al. Model‐based Drug Development , 2007, Clinical pharmacology and therapeutics.
[20] Andreas Krause,et al. Interactive Visualization and Communication for Increased Impact of Pharmacometrics , 2010, Journal of clinical pharmacology.
[21] K Krishnan,et al. A Spreadsheet Program for Modeling Quantitative Structure-Pharmacokinetic Relationships for Inhaled Volatile Organics in Humans , 2005, SAR and QSAR in environmental research.
[22] H Delboy,et al. A non-linear fitting program in pharmacokinetics with Microsoft Excel spreadsheet. , 1994, International journal of bio-medical computing.
[23] P. Marroum,et al. Utilisation of Pharmacokinetic-Pharmacodynamic Modelling and Simulation in Regulatory Decision-Making , 2001, Clinical pharmacokinetics.
[24] Gianne Derks,et al. Mathematical analysis of the pharmacokinetic-pharmacodynamic (PKPD) behaviour of monoclonal antibodies: predicting in vivo potency. , 2011, Journal of theoretical biology.
[25] Donald E. Mager,et al. General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition , 2001, Journal of Pharmacokinetics and Pharmacodynamics.
[26] Neil Benson,et al. Impact of protein binding on receptor occupancy: a two-compartment model. , 2010, Journal of theoretical biology.
[27] Giuseppe De Nicolao,et al. A Minimal Model of Tumor Growth Inhibition , 2008, IEEE Transactions on Biomedical Engineering.
[28] A. Christopoulos,et al. Qualitative and quantitative assessment of relative agonist efficacy. , 1999, Biochemical pharmacology.
[29] Yong Zhang,et al. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel , 2010, Comput. Methods Programs Biomed..
[30] Johan Gabrielsson,et al. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications , 2002 .
[31] Meindert Danhof,et al. Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling. , 2009, Drug metabolism and pharmacokinetics.
[32] C. T. Viswanathan,et al. Opportunities for Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development , 1992, Clinical pharmacology and therapeutics.
[33] Stephen B. Duffull,et al. Estimation of pharmacokinetic parameters from non-compartmental variables using Microsoft Excel® , 2005, Comput. Biol. Medicine.
[34] N. Holford,et al. Clinical Trial Simulation: A Review , 2010, Clinical pharmacology and therapeutics.